Q2 2025 Relmada Therapeutics Inc Earnings Call Transcript

Aug 7, 2025 / 08:30 PM GMT

Release Date Price: $0.6019 (+0.48%)

Transcript 8-K10-Q

Key Points

Positve

Relmada Therapeutics Inc (RLMD) reported impressive 6-month follow-up data for NDVO1, with 91% of patients achieving high-grade disease-free status.
The company has expanded its team with two highly respected experts in bladder cancer and neurological oncology, which is expected to enhance their clinical capabilities.
Relmada Therapeutics Inc (RLMD) has a strong cash balance of $20.6 million and a clean balance sheet, positioning it well for future developments.
The company is preparing to initiate a Phase 3 study for NDVO1 and a Phase 2 study for sopranolone in 2026, indicating a clear path forward for its pipeline.
The addition of NDVO1 and sopranolone to the pipeline aligns with the company's strategic objectives and targets significant, underserved markets.

Negative

Relmada Therapeutics Inc (RLMD) reported a decrease in cash equivalents and short-term investments from $44.9 million at the end of 2024 to $20.6 million as of June 30, 2025.
The company experienced a net loss of $9.9 million for the second quarter of 2025, although this was an improvement from the previous year's loss.
Research and development expenses decreased significantly, which may indicate a slowdown in certain activities as the company prepares for future trials.
The company faces uncertainties related to FDA approval pathways, particularly in deciding between high-grade and low/intermediate-grade bladder cancer markets.
There is a reliance on future FDA interactions to determine the viability of their proposed trial designs, which could impact timelines and strategies.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

RLMD.OQ - Relmada Therapeutics Inc
Q2 2025 Relmada Therapeutics Inc Earnings Call
Aug 07, 2025 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon and welcome to the Ramada Therapeutics 2nd quarter 2025 earnings conference call. At this time, all participants are in a listen-only mode. After the prepared remarks, we will conduct a question and answer session. To ask a question, please press 1.

As a reminder, this conference call is being recorded and will be available for replay on the Role model website.

I would now like to turn the call over to Brian Ritchie from Lifeside Advisors. Please go ahead, Mr. Ritchie.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you.

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.